Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00304590 | Study of XL999 in Patients With Multiple Myeloma | terminated | Phase 2 | 4 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT01070862 | Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.(MAG 2002) | completed | Phase 3 | — | University Hospital, CaenOTHER | 1 | Feb 18, 2010 |
| clinicaltrials |
| NCT00124813 | Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma | unknown | Phase 2 | 80 | University Hospital, BonnOTHER | 1 | Feb 2, 2010 | clinicaltrials |
| NCT00459069 | The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma | completed | Phase 1 | 18 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00571168 | Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy(EmNa) | unknown | Phase 3 | 362 | Heidelberg UniversityOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00229203 | A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma | completed | Phase 2 | 51 | PharmaMarINDUSTRY | 1 | Dec 24, 2009 | clinicaltrials |
| NCT00243763 | TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma | terminated | Phase 1 | 64 | NovartisINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00195533 | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | completed | — | 801 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Nov 16, 2009 | clinicaltrials |
| NCT00988312 | Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma | completed | Phase 1 | 9 | University Hospital Carl Gustav CarusOTHER | 1 | Oct 2, 2009 | clinicaltrials |
| NCT00051116 | A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 100 | Celgene CorporationINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00425347 | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma | completed | Phase 1 | 35 | Facet BiotechINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00391157 | VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma | completed | Phase 2 | 40 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00461747 | GEM05 for Patients With Multiple Myeloma Under 65 Years(GEM05MENOS65) | completed | Phase 3 | 390 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00186316 | Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 25, 2009 | clinicaltrials |
| NCT00327249 | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | — | AmpliMed CorporationINDUSTRY | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00598624 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)(AlloTreo) | unknown | Phase 2 | 175 | IRCCS San RaffaeleOTHER | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00306813 | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of WuerzburgOTHER | 1 | Aug 4, 2009 | clinicaltrials |
| NCT00950768 | Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients | completed | Phase 3 | 298 | Azienda Ospedaliera San Giovanni BattistaOTHER | 0 | Aug 3, 2009 | clinicaltrials |
| NCT00436059 | The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) | completed | Phase 2 | 20 | Vejle HospitalOTHER | 1 | Jul 8, 2009 | clinicaltrials |
| NCT00932217 | Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma | unknown | Phase 3 | 180 | University of PisaOTHER | 0 | Jul 3, 2009 | clinicaltrials |
| NCT00910897 | Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) | unknown | Phase 3 | 205 | Intergroupe Francophone du MyelomeNETWORK | 2 | Jun 1, 2009 | clinicaltrials |
| NCT00910078 | Serum Free Light Change in Multiple Myeloma | completed | — | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | May 29, 2009 | clinicaltrials |
| NCT00781170 | Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma | completed | Phase 2 | 20 | Universitätsklinikum Hamburg-EppendorfOTHER | 0 | May 28, 2009 | clinicaltrials |
| NCT00036023 | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | completed | Phase 2 | — | AmgenINDUSTRY | 0 | May 11, 2009 | clinicaltrials |
| NCT00547404 | Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma | withdrawn | Phase 1 | 35 | Piramal Enterprises LimitedINDUSTRY | 0 | Apr 23, 2009 | clinicaltrials |
| NCT00083564 | Study Comparing STR (Skeletal Targeted Radiotherapy) Plus Melphalan to Melphalan Alone, With Stem Cell Transplant in Multiple Myeloma | terminated | Phase 3 | 240 | Poniard PharmaceuticalsINDUSTRY | 2 | Mar 31, 2009 | clinicaltrials |
| NCT00872352 | Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients | unknown | Phase 3 | 30 | Wolfson Medical CenterOTHER_GOV | 1 | Mar 31, 2009 | clinicaltrials |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 40 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 27, 2009 | clinicaltrials |
| NCT00111319 | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 26, 2009 | clinicaltrials |
| NCT00592579 | A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple Myeloma | completed | Phase 2 | 60 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00200681 | IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma | completed | Phase 3 | 493 | Nantes University HospitalOTHER | 1 | Feb 5, 2009 | clinicaltrials |
| NCT00291538 | Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma | completed | Phase 1 | 20 | Nantes University HospitalOTHER | 1 | Feb 4, 2009 | clinicaltrials |
| NCT00207805 | The Optimal Timing of a Second Autologous Peripheral Blood Stem Cell Transplantation in Patients (<61 Years) With Multiple Myeloma | completed | Phase 3 | 202 | Centre National de Greffe de Moelle OsseuseOTHER_GOV | 1 | Jan 27, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00193544 | Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Jan 23, 2009 | clinicaltrials |
| NCT00039754 | A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | — | Poniard PharmaceuticalsINDUSTRY | 0 | Jan 21, 2009 | clinicaltrials |
| NCT00821301 | Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma | unknown | Phase 1 | 30 | Immune ControlINDUSTRY | 1 | Jan 13, 2009 | clinicaltrials |
| NCT00579917 | Behavioral Intervention For BMT/SCT Survivors(BMT/SCT) | completed | — | 133 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2009 | clinicaltrials |
| NCT00804947 | Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen | unknown | Phase 2 | 50 | Fundacion Para La Investigacion Hospital La FeOTHER | 1 | Dec 9, 2008 | clinicaltrials |
| NCT00560053 | Pethema Multiple Myeloma 2000 | completed | Phase 3 | 500 | PETHEMA FoundationOTHER | 0 | Nov 27, 2008 | clinicaltrials |
| NCT00352742 | A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | AttenuonINDUSTRY | 1 | Oct 28, 2008 | clinicaltrials |
| NCT00415987 | Hematopoietic Stem Cell Transplantation in Myeloma | unknown | Phase 2 / Phase 3 | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00702247 | Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi) | unknown | Phase 2 | — | Azienda Ospedaliera San Giovanni BattistaOTHER | 1 | Jun 20, 2008 | clinicaltrials |
| NCT00200668 | Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients. | terminated | N/A | 0 | Nantes University HospitalOTHER | 1 | Jun 9, 2008 | clinicaltrials |
| NCT00113204 | Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma(IPi-504-01) | completed | Phase 1 | 18 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | May 20, 2008 | clinicaltrials |
| NCT00320476 | VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates | completed | Phase 2 | 35 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00349115 | TCD Followed by autoSCT for Newly Diagnosed MM Patients | unknown | Phase 2 | 43 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00644306 | Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma(IFM 01/01) | terminated | Phase 3 | 232 | Central Hospital, Nancy, FranceOTHER | 1 | Mar 26, 2008 | clinicaltrials |
| NCT00633542 | Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) | completed | Phase 3 | 103 | Università Politecnica delle MarcheOTHER | 1 | Mar 12, 2008 | clinicaltrials |
| NCT00001750 | Comparing Treatments for Multiple Myeloma | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Feb 22, 2010source: clinicaltrials